Skip to main content
Erschienen in: Heart and Vessels 12/2016

14.03.2016 | Original Article

Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry

verfasst von: Yugo Yamashita, Daisuke Takagi, Yasuhiro Hamatani, Moritake Iguchi, Nobutoyo Masunaga, Masahiro Esato, Yeong-Hwa Chun, Hitoshi Itoh, Masato Nishimura, Hiromichi Wada, Koji Hasegawa, Hisashi Ogawa, Mitsuru Abe, Masaharu Akao

Erschienen in: Heart and Vessels | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Atrial fibrillation (AF) is common in dialysis patients. However, clinical characteristics and outcomes of dialysis patients with AF are poorly understood. The Fushimi AF Registry is a community-based prospective survey of AF patients in Japan. Follow-up data were available for 3713 patients with a median follow-up of 2.8 years. We compared clinical characteristics and outcomes between the dialysis group (n = 92; 2.5 %) and others. The dialysis group had more various co-morbidities, with a mean CHADS2 score of 2.5, and the rate of warfarin prescription was 38 %. The annual incidence rates of stroke or systemic embolism (SE), major bleeding, and all-cause death in the dialysis group were 4.0, 5.1, and 20.9 per 100 person-years, respectively. There was no significant difference in the incidence rate of stroke/SE between the dialysis group and the non-dialysis group [hazard ratio (HR) 1.74 (95 % confidence interval (CI) 0.74–3.42)]. The incidence rates of major bleeding, all-cause death, and the composite of stroke/SE and all-cause death in the dialysis group were higher than those in the non-dialysis group [major bleeding: HR 3.09 (95 % CI 1.46–5.72), all-cause death: HR 3.51 (95 % CI 2.48–4.81), the composite of stroke/SE and all-cause death: HR 2.99 (95 % CI 2.15–4.05)]. Among dialysis patients, warfarin did not affect major clinical events including stroke/SE, bleeding or all-cause death. Among AF patients, those receiving dialysis showed higher incidence of major bleeding and all-cause death compared with non-dialysis patients, but the risk of stroke/SE was not particularly high.
Literatur
1.
Zurück zum Zitat Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988CrossRefPubMed Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988CrossRefPubMed
2.
Zurück zum Zitat Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C (2012) Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367:625–635CrossRefPubMed Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C (2012) Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367:625–635CrossRefPubMed
3.
Zurück zum Zitat Poli D, Antonucci E, Zanazzi M, Grifoni E, Testa S, Ageno W, Palareti G (2012) Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Thromb Haemost 107:1100–1106CrossRefPubMed Poli D, Antonucci E, Zanazzi M, Grifoni E, Testa S, Ageno W, Palareti G (2012) Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Thromb Haemost 107:1100–1106CrossRefPubMed
4.
Zurück zum Zitat Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S (2011) The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 22:349–357CrossRefPubMedPubMedCentral Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S (2011) The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 22:349–357CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Genovesi S, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A, Valsecchi MG (2008) Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 51:255–262CrossRefPubMed Genovesi S, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A, Valsecchi MG (2008) Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 51:255–262CrossRefPubMed
6.
Zurück zum Zitat Seliger SL, Gillen DL, Tirschwell D, Wasse H, Kestenbaum BR, Stehman-Breen CO (2003) Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol 14:2623–2631CrossRefPubMed Seliger SL, Gillen DL, Tirschwell D, Wasse H, Kestenbaum BR, Stehman-Breen CO (2003) Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol 14:2623–2631CrossRefPubMed
7.
Zurück zum Zitat Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–867CrossRefPubMed Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–867CrossRefPubMed
8.
Zurück zum Zitat Chan KE, Lazarus JM, Thadhani R, Hakim RM (2009) Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20:2223–2233CrossRefPubMedPubMedCentral Chan KE, Lazarus JM, Thadhani R, Hakim RM (2009) Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20:2223–2233CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK (2011) Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 6:2662–2668CrossRefPubMedPubMedCentral Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK (2011) Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 6:2662–2668CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, Robinson BM (2010) Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 77:1098–1106CrossRefPubMed Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, Robinson BM (2010) Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 77:1098–1106CrossRefPubMed
11.
Zurück zum Zitat Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L (2014) Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 129:1196–1203CrossRefPubMed Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L (2014) Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 129:1196–1203CrossRefPubMed
12.
Zurück zum Zitat Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Ryden LE, Cannom DS, Crijns HJ, Halperin JL, Le Heuzey J, Kay GN, Olsson SB, Prystowsky EN, Tamargo JL (2013) Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 127:1916–1926CrossRefPubMed Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Ryden LE, Cannom DS, Crijns HJ, Halperin JL, Le Heuzey J, Kay GN, Olsson SB, Prystowsky EN, Tamargo JL (2013) Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 127:1916–1926CrossRefPubMed
13.
Zurück zum Zitat Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Europace 14:1385–1413CrossRefPubMed Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Europace 14:1385–1413CrossRefPubMed
14.
Zurück zum Zitat Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E (2011) Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int 80:572–586CrossRefPubMed Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E (2011) Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int 80:572–586CrossRefPubMed
15.
Zurück zum Zitat Hirakata H, Nitta K, Inaba M, Shoji T, Fujii H, Kobayashi S, Tabei K, Joki N, Hase H, Nishimura M, Ozaki S, Ikari Y, Kumada Y, Tsuruya K, Fujimoto S, Inoue T, Yokoi H, Hirata S, Shimamoto K, Kugiyama K, Akiba T, Iseki K, Tsubakihara Y, Tomo T, Akizawa T (2012) Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. Ther Apher Dial 16:387–435CrossRefPubMed Hirakata H, Nitta K, Inaba M, Shoji T, Fujii H, Kobayashi S, Tabei K, Joki N, Hase H, Nishimura M, Ozaki S, Ikari Y, Kumada Y, Tsuruya K, Fujimoto S, Inoue T, Yokoi H, Hirata S, Shimamoto K, Kugiyama K, Akiba T, Iseki K, Tsubakihara Y, Tomo T, Akizawa T (2012) Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. Ther Apher Dial 16:387–435CrossRefPubMed
16.
Zurück zum Zitat Akao M, Chun YH, Esato M, Abe M, Tsuji H, Wada H, Hasegawa K (2014) Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J 78:2166–2172CrossRefPubMed Akao M, Chun YH, Esato M, Abe M, Tsuji H, Wada H, Hasegawa K (2014) Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J 78:2166–2172CrossRefPubMed
17.
Zurück zum Zitat Akao M, Chun YH, Wada H, Esato M, Hashimoto T, Abe M, Hasegawa K, Tsuji H, Furuke K (2013) Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol 61:260–266CrossRefPubMed Akao M, Chun YH, Wada H, Esato M, Hashimoto T, Abe M, Hasegawa K, Tsuji H, Furuke K (2013) Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol 61:260–266CrossRefPubMed
18.
Zurück zum Zitat Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870CrossRefPubMed Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870CrossRefPubMed
19.
Zurück zum Zitat Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272CrossRefPubMed Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272CrossRefPubMed
20.
Zurück zum Zitat Liao JN, Chao TF, Liu CJ, Wang KL, Chen SJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Chen SA (2015) Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int 87:1209–1215CrossRefPubMed Liao JN, Chao TF, Liu CJ, Wang KL, Chen SJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Chen SA (2015) Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int 87:1209–1215CrossRefPubMed
21.
Zurück zum Zitat Vazquez E, Sanchez-Perales C, Borrego F, Garcia-Cortes MJ, Lozano C, Guzman M, Gil JM, Borrego MJ, Perez V (2000) Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 140:886–890CrossRefPubMed Vazquez E, Sanchez-Perales C, Borrego F, Garcia-Cortes MJ, Lozano C, Guzman M, Gil JM, Borrego MJ, Perez V (2000) Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 140:886–890CrossRefPubMed
22.
Zurück zum Zitat Vazquez E, Sanchez-Perales C, Lozano C, Garcia-Cortes MJ, Borrego F, Guzman M, Perez P, Pagola C, Borrego MJ, Perez V (2003) Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 92:868–871CrossRefPubMed Vazquez E, Sanchez-Perales C, Lozano C, Garcia-Cortes MJ, Borrego F, Guzman M, Perez P, Pagola C, Borrego MJ, Perez V (2003) Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 92:868–871CrossRefPubMed
23.
Zurück zum Zitat Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D, Balcke P (2001) Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol 21:35–39CrossRefPubMed Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D, Balcke P (2001) Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol 21:35–39CrossRefPubMed
24.
Zurück zum Zitat Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Liao JN, Chen TJ, Lip GY, Chen SA (2014) Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm 11:1752–1759CrossRefPubMed Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Liao JN, Chen TJ, Lip GY, Chen SA (2014) Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm 11:1752–1759CrossRefPubMed
25.
Zurück zum Zitat Mega JL (2011) A new era for anticoagulation in atrial fibrillation. N Engl J Med 365:1052–1054CrossRefPubMed Mega JL (2011) A new era for anticoagulation in atrial fibrillation. N Engl J Med 365:1052–1054CrossRefPubMed
26.
Zurück zum Zitat Clase CM, Holden RM, Sood MM, Rigatto C, Moist LM, Thomson BK, Mann JF, Zimmerman DL (2012) Should patients with advanced chronic kidney disease and atrial fibrillation receive chronic anticoagulation? Nephrol Dial Transplant 27:3719–3724CrossRefPubMed Clase CM, Holden RM, Sood MM, Rigatto C, Moist LM, Thomson BK, Mann JF, Zimmerman DL (2012) Should patients with advanced chronic kidney disease and atrial fibrillation receive chronic anticoagulation? Nephrol Dial Transplant 27:3719–3724CrossRefPubMed
27.
Zurück zum Zitat Chan KE, Lazarus JM, Thadhani R, Hakim RM (2009) Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 20:872–881CrossRefPubMedPubMedCentral Chan KE, Lazarus JM, Thadhani R, Hakim RM (2009) Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 20:872–881CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM (2004) Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15:2857–2867CrossRefPubMed Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM (2004) Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15:2857–2867CrossRefPubMed
29.
Zurück zum Zitat Findlay MD, Thomson PC, Fulton RL, Solbu MD, Jardine AG, Patel RK, Stevens KK, Geddes CC, Dawson J, Mark PB (2015) Risk factors of ischemic stroke and subsequent outcome in patients receiving hemodialysis. Stroke 46:2477–2481CrossRefPubMed Findlay MD, Thomson PC, Fulton RL, Solbu MD, Jardine AG, Patel RK, Stevens KK, Geddes CC, Dawson J, Mark PB (2015) Risk factors of ischemic stroke and subsequent outcome in patients receiving hemodialysis. Stroke 46:2477–2481CrossRefPubMed
31.
Zurück zum Zitat Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW (2015) Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 131:972–979CrossRefPubMedPubMedCentral Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW (2015) Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 131:972–979CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Shen JI, Montez-Rath ME, Lenihan CR, Turakhia MP, Chang TI, Winkelmayer WC (2015) Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis 66:677–688CrossRefPubMedPubMedCentral Shen JI, Montez-Rath ME, Lenihan CR, Turakhia MP, Chang TI, Winkelmayer WC (2015) Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis 66:677–688CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Li J, Wang L, Hu J, Xu G (2015) Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: a systematic review and a meta-analysis. Nutr Metab Cardiovasc Dis 25:706–713CrossRefPubMed Li J, Wang L, Hu J, Xu G (2015) Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: a systematic review and a meta-analysis. Nutr Metab Cardiovasc Dis 25:706–713CrossRefPubMed
34.
Zurück zum Zitat Dahal K, Kunwar S, Rijal J, Schulman P, Lee J (2015) Stroke, major bleeding and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest. doi: 10.1378/chest.15-1719 Dahal K, Kunwar S, Rijal J, Schulman P, Lee J (2015) Stroke, major bleeding and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest. doi: 10.​1378/​chest.​15-1719
35.
Zurück zum Zitat Yodogawa K, Mii A, Fukui M, Iwasaki YK, Hayashi M, Kaneko T, Miyauchi Y, Tsuruoka S, Shimizu W (2015) Warfarin use and incidence of stroke in Japanese hemodialysis patients with atrial fibrillation. Heart Vessels. doi:10.1007/s00380-015-0777-7 PubMed Yodogawa K, Mii A, Fukui M, Iwasaki YK, Hayashi M, Kaneko T, Miyauchi Y, Tsuruoka S, Shimizu W (2015) Warfarin use and incidence of stroke in Japanese hemodialysis patients with atrial fibrillation. Heart Vessels. doi:10.​1007/​s00380-015-0777-7 PubMed
36.
Zurück zum Zitat Marinigh R, Lane DA, Lip GY (2011) Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 57:1339–1348CrossRefPubMed Marinigh R, Lane DA, Lip GY (2011) Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 57:1339–1348CrossRefPubMed
37.
Zurück zum Zitat To AC, Yehia M, Collins JF (2007) Atrial fibrillation in haemodialysis patients: do the guidelines for anticoagulation apply? Nephrol (Carlton) 12:441–447CrossRef To AC, Yehia M, Collins JF (2007) Atrial fibrillation in haemodialysis patients: do the guidelines for anticoagulation apply? Nephrol (Carlton) 12:441–447CrossRef
38.
Zurück zum Zitat Nakai S, Hanafusa N, Masakane I, Taniguchi M, Hamano T, Shoji T, Hasegawa T, Itami N, Yamagata K, Shinoda T, Kazama JJ, Watanabe Y, Shigematsu T, Marubayashi S, Morita O, Wada A, Hashimoto S, Suzuki K, Nakamoto H, Kimata N, Wakai K, Fujii N, Ogata S, Tsuchida K, Nishi H, Iseki K, Tsubakihara Y (2014) An overview of regular dialysis treatment in Japan (as of 31 December 2012). Ther Apher Dial 18:535–602CrossRefPubMed Nakai S, Hanafusa N, Masakane I, Taniguchi M, Hamano T, Shoji T, Hasegawa T, Itami N, Yamagata K, Shinoda T, Kazama JJ, Watanabe Y, Shigematsu T, Marubayashi S, Morita O, Wada A, Hashimoto S, Suzuki K, Nakamoto H, Kimata N, Wakai K, Fujii N, Ogata S, Tsuchida K, Nishi H, Iseki K, Tsubakihara Y (2014) An overview of regular dialysis treatment in Japan (as of 31 December 2012). Ther Apher Dial 18:535–602CrossRefPubMed
39.
Zurück zum Zitat Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW (2003) Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14:3270–3277CrossRefPubMed Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW (2003) Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14:3270–3277CrossRefPubMed
Metadaten
Titel
Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry
verfasst von
Yugo Yamashita
Daisuke Takagi
Yasuhiro Hamatani
Moritake Iguchi
Nobutoyo Masunaga
Masahiro Esato
Yeong-Hwa Chun
Hitoshi Itoh
Masato Nishimura
Hiromichi Wada
Koji Hasegawa
Hisashi Ogawa
Mitsuru Abe
Masaharu Akao
Publikationsdatum
14.03.2016
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 12/2016
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-016-0818-x

Weitere Artikel der Ausgabe 12/2016

Heart and Vessels 12/2016 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.